168 related articles for article (PubMed ID: 38441216)
1. Emotional Blunting in Depression in the PREDDICT Clinical Trial: Inflammation-Stratified Augmentation of Vortioxetine With Celecoxib.
Sampson E; Kavakbasi E; Mills NT; Hori H; Schubert KO; Fourrier C; Baune BT
Int J Neuropsychopharmacol; 2024 Mar; 27(3):. PubMed ID: 38441216
[TBL] [Abstract][Full Text] [Related]
2. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C
Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
4. Inflammation-stratified augmentation of vortioxetine with celecoxib: Results from a double-blind, randomized, placebo-controlled trial in major depressive disorder.
Kavakbasi E; Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert KO; Clark SR; Fourrier C; Baune BT
J Neurochem; 2023 Aug; ():. PubMed ID: 37635396
[TBL] [Abstract][Full Text] [Related]
5. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial.
Mills NT; Sampson E; Fourrier C; Baune BT
Int J Neuropsychopharmacol; 2021 Apr; 24(4):314-321. PubMed ID: 33269395
[TBL] [Abstract][Full Text] [Related]
6. Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert O; Clark SR; Fourrier C; Baune BT
J Clin Psychiatry; 2023 Oct; 84(6):. PubMed ID: 37796652
[No Abstract] [Full Text] [Related]
7. Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting.
Christensen MC; Fagiolini A; Florea I; Loft H; Cuomo A; Goodwin GM
J Affect Disord; 2021 Nov; 294():924-931. PubMed ID: 34378539
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
Fagiolini A; Florea I; Loft H; Christensen MC
J Affect Disord; 2021 Mar; 283():472-479. PubMed ID: 33516560
[TBL] [Abstract][Full Text] [Related]
9. The Motivation and Energy Inventory (MEI): Analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study.
Christensen MC; Adair M; Loft H; McIntyre RS
J Affect Disord; 2023 Feb; 323():547-553. PubMed ID: 36395989
[TBL] [Abstract][Full Text] [Related]
10. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
Nierenberg AA; Loft H; Olsen CK
J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
12. Exploratory study of association between blood immune markers and cognitive symptom severity in major depressive disorder: Stratification by body mass index status.
Fourrier C; Sampson E; Hori H; Schubert KO; Clark S; Mills NT; Baune BT
Brain Behav Immun; 2020 Aug; 88():242-251. PubMed ID: 32526448
[TBL] [Abstract][Full Text] [Related]
13. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial.
Jacobsen P; Zhong W; Nomikos G; Clayton A
J Sex Med; 2019 Oct; 16(10):1638-1649. PubMed ID: 31405765
[TBL] [Abstract][Full Text] [Related]
14. Emotional blunting with bupropion and serotonin reuptake inhibitors in three randomized controlled trials for acute major depressive disorder.
Peters EM; Balbuena L; Lodhi RJ
J Affect Disord; 2022 Dec; 318():29-32. PubMed ID: 36029876
[TBL] [Abstract][Full Text] [Related]
15. Vortioxetine for depression in adults.
Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
[TBL] [Abstract][Full Text] [Related]
16. S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial.
Sarris J; Murphy J; Stough C; Mischoulon D; Bousman C; MacDonald P; Adams L; Nazareth S; Oliver G; Cribb L; Savage K; Menon R; Chamoli S; Berk M; Ng CH; Byrne GJ
Psychopharmacology (Berl); 2020 Jan; 237(1):209-218. PubMed ID: 31712971
[TBL] [Abstract][Full Text] [Related]
17. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
Inoue T; Nishimura A; Sasai K; Kitagawa T
Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
[TBL] [Abstract][Full Text] [Related]
18. Emotional blunting with antidepressant treatments: A survey among depressed patients.
Goodwin GM; Price J; De Bodinat C; Laredo J
J Affect Disord; 2017 Oct; 221():31-35. PubMed ID: 28628765
[TBL] [Abstract][Full Text] [Related]
19. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
20. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
